Evotec SE (EVO) Restructuring Costs (2009 - 2025)
Evotec SE (EVO) posted Restructuring Costs of -$1629.7 for Q4 2025, down 1390.74% sequentially from $126.26 in Q3 2025, and down 121.48% YoY from $7587.0 in Q4 2024.
Evotec SE (EVO) Restructuring Costs (2009 - 2025) Analysis & Trends
Evotec SE has reported Restructuring Costs for 3 years, with the latest figure at -$1629.7 in Q4 2025.
- Quarterly Restructuring Costs fell 121.48% year-over-year to -$1629.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12891.5 (down 99.68% YoY) and the FY2025 annual result came in at -$698.43, up 98.81% from the prior year.
- Restructuring Costs fell to -$1629.7 in Q4 2025 per EVO's latest filing, from $126.26 in the prior quarter.
- Over five years, Restructuring Costs peaked at $7587.0 in Q4 2024 and troughed at -$1629.7 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Evotec SE | 681.90 Mn | 681.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,629.66 |
| Sep 30, 2025 | 126.26 |
| Dec 31, 2024 | 7,587.03 |
| Sep 30, 2024 | 6,807.86 |
| Dec 31, 2009 | 3.98 Mn |
| Jun 30, 2009 | 3,665.56 |
| Mar 31, 2009 | 1.89 |